Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Answer: If you buy and hold Fate Therapeutics stock, the expectation is over time the near term fluctuations will cancel out, and the long-term positive trend will favor you - at least if the company is otherwise strong. Posted by MarketBeat News on Mar 2nd, 2023. | March 3, 2023 The partnership will leverage San Diego-based Fate Therapeutics induced pluripotent stem cell (iPSC) product platform and Janssens proprietary tumor-targeting antigen binders to create novel CAR NK and CAR T-Cell product candidates that will be developed against up to four tumor-associated antigens for hematologic malignancies and solid tumors. The stock price of Fate Therapeutics (NASDAQ: FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a large 20%. Reserve Your Spot With These Hotels The Analysts Support, Cruise Line Stocks Still Have Some Choppy Waters to Navigate, Four Vegan Food Stocks Performing Beyond the Norm, MarketBeat.com's FREE daily email newsletter, Kroger Shares Gap Up on Better-Than-Expected Earnings. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, beating analysts' consensus estimates of ($0.86) by $0.28. Additionally, Fate has the right to co-commercialize the candidates should they be approved and share equally in profits and losses, the company said in its announcement. Fate has been focused on the oncology and immunology pipeline for multiple cancer types including myeloid leukemia, B-cell lymphoma, and multiple myeloma among others. The firm owned 161,373 shares of the biopharmaceutical companys stock after selling 59,987 shares during the quarter. One share of FATE stock can currently be purchased for approximately $6.11. Last updated: Feb 26, 2023 Powered by IT Spend by Aberdeen This year, Fate Therapeutics is projected to spend $682.2K on IT, according to Aberdeen. Moderna leans into oncology with CytomX deal worth up to $1.2B Fate ends potential $3B Janssen partnership. FT819 is a first-of-kind, allogeneic, off-the-shelf CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line precisely engineered to insert a novel 1XX anti-CD19 chimeric antigen receptor (CAR) under the regulation of the T-cell receptor alpha constant (TRAC) locus for optimized control of anti-tumor activity and to completely delete T-cell receptor (TCR . Get daily stock ideas from top-performing Wall Street analysts. Per deal terms, J&J will buy $50 million Fate shares at $31 apiece,a roughly 47% premium to Fate's $21.07 closing price on Thursday. Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass-produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment, the company said. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares. If response rates for its treatments fall, as is usually the case in cancer trials, this stock . View analysts price targets for FATE or view top-rated stocks among Wall Street analysts. Subscribe to BioPharma Dive for top news, trends & analysis, The free newsletter covering the top industry headlines, By Christopher Newman and Jonathan Gardner , A preclinical trial by the U.S. National Institutes of Health validates the efficacy of Uric A, EUCOPE adds nine new innovative members to its network, From EUCOPE - European Confederation of Pharmaceutical Entrepreneurs, Ymmunobio Welcomes Dr. Kanda and Dr. Khairnar to Advisory Board, Vial Announces the Addition of Dr. Rajat N Agrawal to their Ophthalmology CRO Scientific Advis, By signing up to receive our newsletter, you agree to our, disrupting study enrollment and treatment, Bayer backs cell therapy startup with $215M in funding, Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work, 5 questions facing the pharma industry in 2023, FDA clears Intellia to start US tests of in vivo gene editing drug, Novartis takes step toward expanding supply of in-demand cancer drug, Bristol Myers, J&J plan tests of new blood thinner in nearly 50,000 patients, Exelixis reports trial failure for cancer drug combination, How to Implement a Healthy Content Moderation Strategy, How To Build Affordability Programs With Real-time Data, FDA has new power to hold drugmakers accountable. Notably, though, the stock is likely to beat S&P500 returns by 4% over the next month (twenty-one trading days). Published: Apr 03, 2020 Going by historical performance, there is roughly an equal chance of a rise or fall in FATE stock over the next month. On average, they anticipate the company's stock price to reach $24.69 in the next year. The biotech Nektar Therapeutics said late Monday that it would cut 70% of its workforce in an effort to extend its cash runway after the failure of its cancer drug partnership with Bristol Myers. PNC Financial Services Group Inc. now owns 6,737 shares of the biopharmaceutical companys stock worth $260,000 after buying an additional 986 shares during the last quarter. Specifically, ARK Genomic Revolution ETF ( NYSEARCA: ARKG) bought 55,163 shares of Fate Therapeutics, and ARK Innovation ETF ( NYSEARCA: ARKK) bought 186,114 shares. Also, CEO J Scott Wolchko sold 45,907 shares of the stock in a transaction dated Tuesday, January 10th. Given the current momentum in the stock, and based on our machine learning analysis of trends in the stock price over the last few years, we believe that there is an 64% chance of a rise in FATE stock over the next month (twenty one trading days). The. Quantbot Technologies LP bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $69,000. According to the Trefis Machine Learning Engine, which identifies trends in a companys stock price using historical stock data, returns for FATE stock average around 6% in the next one-month (twenty-one trading days) period after experiencing a 5% fall in a week (five trading days). Finally, PNC Financial Services Group Inc. increased its holdings in shares of Fate Therapeutics by 17.1% during the 1st quarter. The company is currently working on multiple programs, including FT516 for the treatment of acute myeloid leukemia and B-cell lymphoma, FT596 to treat B-cell lymphoma, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT500, FT516, FT-ONO2, and FATE-NK100 for the treatment of advanced solid tumors. But now that the stock has fallen 20% in just five days, will the FATE stock resume its downward trajectory over the coming weeks, or is a rise in the stock imminent? Therefore we cannot guarantee that our site fully works in Internet Explorer. How were Fate Therapeutics' earnings last quarter? Do Wall Street analysts like Fate Therapeutics more than its competitors? Using the recent trend (20% fall in a week) and seven years of historical stock data, the Trefis AI engine finds that the stock will likely move 15.1% over the next one month (twenty-one trading days), outperforming the broader indices. Topics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. In comparison, the S&P 500 has an average return of 3.1% over the next 21 trading days under Case 1, and an average return of just 0.5% for Case 2 as detailed in our dashboard that details the average return for the S&P 500 after a fall or rise. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. This historical pattern reflects 178 out of 352, or about 49% chance of gain in FATE stock over the coming month. In fact, the average price estimate for FATE stock is $112, reflecting a large 40% premium to the current market price of $79. Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. First-generation autologous CAR-T therapies involve genetically edited immune cells taken directly from patients in a lengthy, logistically challenging and costly procedure. Once Janssen takes over the program, Fate will then be eligible to receive payments of up to $1.8 billion upon the achievement of development and regulatory milestones and up to $1.2 billion upon the achievement of commercial milestones. The outperformance of FATE can be attributed to positive findings from early clinical trials of FT500 and FT516 treatments. But now that the stock has fallen 20% in just five days, will the FATE stock resume its downward trajectory over the coming weeks, or is a rise in the stock imminent? The company employs 449 workers across the globe. Purchases New Holdings in Ball Co. (NYSE:BALL), Blueshift Asset Management LLC Sells 21,016 Shares of Dell Technologies Inc. (NYSE:DELL), Cary Street Partners Investment Advisory LLC Has $126,000 Stock Holdings in Yum China Holdings, Inc. (NYSE:YUMC). Zscaler, Inc Plummets, Is It Time To Buy The Dip? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. See our analysis on Fate Therapeutics Stock Chances of Rise for more details. Stifel Nicolaus cut shares of Fate Therapeutics from a buy rating to a hold rating in a research note on Friday, January 6th. It's an emerging field of research that's still in its early stages. Top institutional shareholders include ARK Investment Management LLC (4.34%), Millennium Management LLC (2.95%), Price T Rowe Associates Inc. MD (2.74%), Renaissance Technologies LLC (1.86%), Morgan Stanley (1.79%) and Geode Capital Management LLC (1.61%). Shares of FATE stock can be purchased through any online brokerage account. Real-time analyst ratings, insider transactions, earnings data, and more. How much money does Fate Therapeutics make? Interestingly, though, if a stock has gained over the last few days, you would do better to avoid short-term bets for most stocks - although FATE stock appears to be an exception to this general observation. It appears so. That said, the treatment is still in the very early stages of clinical trials, implying there is still some time before the drug can even move to late stage trials, let alone file for approval subject to a positive outcome of the upcoming studies. The average twelve-month price prediction for Fate Therapeutics is $24.69 with a high price target of $90.00 and a low price target of $7.00. Today it has 9 INDs, more than 250. American Consumer News, LLC dba MarketBeat 2010-2023. You can test the chance of recovery over different time intervals of a quarter, month, or even just one day! The outperformance of FATE can be attributed to positive findings from early clinical trials of FT500 and FT516 treatments. Earnings for Fate Therapeutics are expected to grow in the coming year, from ($2.16) to ($2.13) per share. Question 3: What about the average return after a rise if you wait for a while? Scott Wolchko has an approval rating of 100% among the company's employees. Fate Therapeutics (NASDAQ:FATE Get Rating) was upgraded by equities researchers at StockNews.com from a sell rating to a hold rating in a research note issued on Thursday. It does make sense given oncology is a high value market and a single drug approval in this space would mean a significant growth in the companys sales from the $20 million currently. You may opt-out by. Twitter. And it couldnt be more wrong! Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Mr. Beitel is responsible for developing and implementing strategic growth initiatives. Segall Bryant & Hamill LLC's holdings in Fate Therapeutics [] The revenues are expected to see a sharp jump of over 90% to $20.4 million in 2020, due to collaboration agreements with Janssen and Ono. But pharma has made notable investments in the work, which could lead to treatments that are quicker and less costly to produce than their autologous counterparts. In announcing the J&J deal, Fate also warned of coronavirus-related "delays or disruptions in patient enrollment and site initiation" that will affect the timing of its clinical trials. WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the "Class Period"). About FT516 FT516 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line . Now that the stock has seen a strong run up over the recent months, and given that the company is far away from any significant revenue growth, we believe that it is vulnerable to downside risk. The coronavirus pandemic, however, has threatened clinical research timelines across the industry, disrupting study enrollment and treatment. NEW YORK, March 4, 2023 /PRNewswire/ --. Lazard Asset Management LLC lessened its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Rating) by 27.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. Dive Brief: Johnson & Johnson will pay Fate Therapeutics $100 million to co-develop a group of allogeneic, or "off-the-shelf" cell therapies for cancer. Some Fun Scenarios, FAQs & Making Sense of Fate Therapeutics Stock Movements: Question 1: Is the average return for Fate Therapeutics stock higher after a drop? Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. Answer: The average return after a rise is understandably lower than a fall as detailed in the previous question. J&J sues Amgen over plan to sell ulcerative colitis drug similar to Stelara. My No. However, looking at the P/S for Fate is not helpful given the company doesnt have any marketable product yet, and it is more of a story of exciting products in the pipeline. No additional study drug will be given, but subjects can receive other therapies for their cancer while they . Identify stocks that meet your criteria using seven unique stock screeners. BOSTON, MA / ACCESSWIRE / February 28, 2023 / Block & Leviton announces that a class action lawsuit has been filed against Fate Therapeutics, Inc. (NASDAQ:FATE) for securities law violations. Given that the company does not have any marketable products currently, it generates revenues primarily from collaboration with other pharmaceutical companies. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. It is a leading allogeneic (off-the-shelf) NK cell therapy developer which had just 1 IND, 87 employees, and $78mn in cash in 2018. In the past three months, Fate Therapeutics insiders have bought 75.98% more of their company's stock than they have sold. Fate has been focused on the oncology and immunology pipeline for multiple cancer types including myeloid leukemia, B-cell lymphoma, and multiple myeloma among others. Zoom Video Communications, Inc. (NASDAQ:ZM) Shares Acquired by BlackRock Inc. BlackRock Inc. Lowers Position in APA Co. (NASDAQ:APA), Piper Sandler Boosts Duolingo (NYSE:DUOL) Price Target to $127.00, BlackRock Inc. Cuts Holdings in NortonLifeLock Inc. (NASDAQ:NLOK), Altair Engineering Inc. (NASDAQ:ALTR) Insider Sells $161,325.00 in Stock, Caisse DE Depot ET Placement DU Quebec Has $2.15 Million Position in Franklin Resources, Inc. (NYSE:BEN), Capital Fund Management S.A. Makes New Investment in CVR Energy, Inc. (NYSE:CVI), 12,000 Shares in Stratasys Ltd. (NASDAQ:SSYS) Purchased by Gabelli Funds LLC. Assignee: FATE THERAPEUTICS, INC. MACHINE LEARNING ENGINE try it yourself: IF FATE stock moved by -5% over five trading days, THEN over the next twenty-one trading days, FATE stock moves an average of 6%, which implies an excess return of 4% compared to the S&P500. Fate Therapeutics (NASDAQ:FATE) Price Target Lowered to $7.00 at Piper Sandler, Fate Therapeutics (NASDAQ:FATE) Receives "Buy" Rating from EF Hutton Acquisition Co. Try the Trefis machine learning engine above to see for yourself how Fate Therapeutics stock is likely to behave after any specific gain or loss over a period. But how would these numbers change if you are interested in holding FATE stock for a shorter or a longer time period? Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. [4] Through the years, many have been acquired . How do I buy shares of Fate Therapeutics? For example, youll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck.See allTrefis Featured AnalysesandDownloadTrefis Datahere, This is a BETA experience. Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE.". At Tuesday's closing price,. He said the collaboration combines Janssens deep domain expertise in oncology, along with their proprietary technologies for targeting and binding certain tumors with Fates iPSC product platform to develop novel off-the-shelf CAR NK and T-cell cancer immunotherapies. February 28, 2023 - 10:35 am. The shares were sold at an average price of $5.24, for a total transaction of $240,552.68. By Alex Keown. The definitive agreement will see the payment of up to $1bn to Exonics' equity holders if future development and regulatory milestones are met for certain programmes. The early stage company is also eligible to receive up to $1.8 billion in development and. Now that the stock has seen a strong run up over the recent months, and given that the company is far away from any significant revenue growth, we believe that it is vulnerable to downside risk. Currency in USD Follow 2W 10W 9M 6.11 +0.02 (+0.33%) At close: 04:00PM EST 6.29 +0.18 (+2.95%) After hours: 05:58PM EST. Fates iPSC platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses, according to the company. The stock has a market capitalization of $599.76 million, a P/E ratio of -2.10 and a beta of 1.53. Following the sale, the chief executive officer now owns 385,639 shares of the companys stock, valued at approximately $2,020,748.36. Envestnet Asset Management Inc. boosted its stake in Fate Therapeutics by 20.0% in the 1st quarter. Separately, Fate Therapeutics Chief Scientific Officer - Daniel Shoemaker - will be leaving the company in June this year, and this development has likely hurt the stock. Raymond James & Associates raised its stake in Fate Therapeutics by 42.6% during the first quarter. In-depth profiles and analysis for 20,000 public companies. The stock price of Fate Therapeutics has seen a solid 16% rise over the last five trading days, while its up 13% over the last ten trading days, and we believe the rally may continue in the near term. A change of 16% or more over 5 trading days is a 9% likelihood event, which has occurred 114 times out of 1256 in the last 5 years, A change of 13% or more over 10 trading days is a 20% likelihood event, which has occurred 252 times out of 1240 in the last 5 years. The data from the trials showed that eight of eleven patients being evaluated for assessment of safety and efficacy of the FT516 treatment achieved an objective response, while six of those patients achieved a complete response. More importantly, there is 60% probability of a positive return over the next twenty-one trading days and a 53% probability of a positive excess return after a -5% change over five trading days, based on historical data. Fate Therapeutics had a negative trailing twelve-month return on equity of 50.86% and a negative net margin of 292.55%. The company said late Thursday it is working on a treatment for a blood . With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! New York, NY-based Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of the central nervous system, disorders for which there are limited. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The two will work on cancer immunotherapies for blood cancers and solid tumors. Insiders have sold a total of 75,708 shares of company stock worth $396,710 in the last ninety days. General & Administrative expenses jumped to $12.5 million from $7.7 million in the year-ago. Is the average return for Fate Therapeutics stock higher over the subsequent month after Case 1 or Case 2? The companys approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. The J&J partnership does give Fate some breathing room. . Fate Therapeutics reported new results for two early-stage studies testing two different types of experimental lymphoma treatments that utilize natural killer cells, a fast-emerging form of cancer immunotherapy. Powered by Madgex Job Board Software. 22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. Citi analyst Yigal Nochomovitz lowered the firm's price target on Fate Therapeutics to $9 from $80 and keeps a Buy rating on the shares. You may opt-out by. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. The company's average rating score is 2.18, and is based on 6 buy ratings, 14 hold ratings, and 2 sell ratings. FATE Fate Therapeutics Inc 6,209 $6.11 $0.02 (0.33%) Today Market Cap $583.99M Volume (M) 1.52M 52-Wk High $43.12 52-Wk Low $4.02 About Feed Sentiment Fundamentals News There is no chart data available for this period 1d 1w 1m 3m 6m 1y All Sentiment Score Message Volume Score Disclaimer: This is informational only. Now, is FATE stock poised to gain further? Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications. Boothbay Fund Management LLC Purchases Shares of 4,711 Graco Inc. UBS Group AG Reduces Stock Holdings in Builders FirstSource, Inc. (NYSE:BLDR), Boothbay Fund Management LLC Has $299,000 Stock Holdings in GMS Inc. (NYSE:GMS), Alphabet Inc. (NASDAQ:GOOG) Shares Bought by Capital Square LLC, Jeereddi Investments LP Increases Position in Alphabet Inc. (NASDAQ:GOOG), Boothbay Fund Management LLC Buys Shares of 4,680 Sonoco Products (NYSE:SON), Boothbay Fund Management LLC Purchases Shares of 4,711 Graco Inc. (NYSE:GGG), MML Investors Services LLC Buys 3,360 Shares of Wolfspeed, Inc. (NYSE:WOLF), Boothbay Fund Management LLC Takes Position in Loews Co. (NYSE:L), Boothbay Fund Management LLC Sells 9,611 Shares of Portillos Inc. (NASDAQ:PTLO), MML Investors Services LLC Sells 139 Shares of Extra Space Storage Inc. (NYSE:EXR), Lazard Asset Management LLC Has $308,000 Stake in Marqeta, Inc. (NASDAQ:MQ), Lazard Asset Management LLC Has $329,000 Position in The Williams Companies, Inc. (NYSE:WMB), Boothbay Fund Management LLC Invests $267,000 in Synaptics Incorporated (NASDAQ:SYNA), 7,728 Shares in SEI Investments (NASDAQ:SEIC) Acquired by Ergoteles LLC, Lazard Asset Management LLC Trims Stake in iQIYI, Inc. (NASDAQ:IQ), 2,549 Shares in Hess Co. (NYSE:HES) Acquired by Boothbay Fund Management LLC, The Interpublic Group of Companies, Inc. (NYSE:IPG) Shares Sold by Lazard Asset Management LLC, Boothbay Fund Management LLC Acquires 38,651 Shares of Consolidated Communications Holdings, Inc. (NASDAQ:CNSL), Boothbay Fund Management LLC Takes $260,000 Position in Advanced Drainage Systems, Inc. (NYSE:WMS), Boothbay Fund Management LLC Takes $288,000 Position in ShotSpotter, Inc. (NASDAQ:SSTI). Fate Therapeutics will receive a $50 million upfront payment and a $50 million equity investment. Young wrote the deal is also "a strong validation" of Fate's approach, which draws from stem cell and CAR-T technologies. Notably, though, the stock is likely to beat S&P500 returns by 4% over the next month (twenty-one trading days). How to Decide, Taiwan Semiconductor Manufacturing Expanding in the West, MarketBeat.com's FREE daily email newsletter. Here's what Wall Street expects from Fate Therapeutics's earnings report, Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates, Fate Therapeutics GAAP EPS of -$0.58 beats by $0.29, revenue of $44.34M beats by $25.93M, FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus, Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Price Target at $26.14, NK Cell Therapy Market 2023 to 2026 CONSUMER INSIGHTS with Dynamics Scenario, Induced Pluripotent Stem Cells (iPSCs) Market Size, Share & Trends Analysis Forecast Report by 2028, Fate Therapeutics (NASDAQ:FATE) Stock Price Down 7%, Natural Killer Cell Therapy Market Size 2023 NEWEST INDUSTRY DATA with Recent Industry Developments till 2028, Natural Killer Cell Therapy Market (New Insights Report) By 2023 which is Booming Strong Growth in the Globe till 2028, FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit, Fate Therapeutics, Inc. (FATE) Class Action: Contact Robbins LLP for Information Regarding the Class Action and Lead Plaintiff Deadline, Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session, Needham Reaffirms Their Buy Rating on G1 Therapeutics (GTHX), Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results, ALERT: Investors in Fate Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FATE, CLASS ACTION UPDATE for AVYA, FATE and PHI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders, CLASS ACTION UPDATE for ENVX, YMAB and FATE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders, view top-rated stocks among Wall Street analysts, 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121.